WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H5351001
CAS#: 1020567-30-9 (free)
Description: GSK2324 is a FXR agonist (EC50 = 50 nM, 102% efficacy).
Hodoodo Cat#: H5351001
Name: GSK2324
CAS#: 1020567-30-9 (free)
Chemical Formula: C29H22Cl2N2O4
Exact Mass: 532.10
Molecular Weight: 533.405
Elemental Analysis: C, 65.30; H, 4.16; Cl, 13.29; N, 5.25; O, 12.00
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 1020567-30-9 (free) 1020567-67-2 (potassium) 1020567-72-9 (sodium),
Synonym: GSK2324; GSK-2324; GSK 2324;
IUPAC/Chemical Name: 6-(4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)phenyl)quinoline-2-carboxylic acid
InChi Key: SZUHDKKQQZPOGX-UHFFFAOYSA-N
InChi Code: InChI=1S/C29H22Cl2N2O4/c1-16(2)28-21(27(33-37-28)26-22(30)4-3-5-23(26)31)15-36-20-10-6-17(7-11-20)18-8-12-24-19(14-18)9-13-25(32-24)29(34)35/h3-14,16H,15H2,1-2H3,(H,34,35)
SMILES Code: ClC1=CC=CC(Cl)=C1C2=NOC(C(C)C)=C2COC3=CC=C(C4=CC(C=CC(C(O)=O)=N5)=C5C=C4)C=C3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 533.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Tarling EJ, Ahn H, de Aguiar Vallim TQ. The nuclear receptor FXR uncouples the
actions of miR-33 from SREBP-2. Arterioscler Thromb Vasc Biol. 2015
Apr;35(4):787-95. doi: 10.1161/ATVBAHA.114.304179. Epub 2015 Jan 15. PubMed PMID:
25593129; PubMed Central PMCID: PMC4376635.
2: Vickers KC, Rader DJ. Nuclear receptors and microRNA-144 coordinately regulate
cholesterol efflux. Circ Res. 2013 Jun 7;112(12):1529-31. doi:
10.1161/CIRCRESAHA.113.301422. PubMed PMID: 23743223; PubMed Central PMCID:
PMC4043301.
3: de Aguiar Vallim TQ, Tarling EJ, Kim T, Civelek M, Baldán Á, Esau C, Edwards
PA. MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma
high-density lipoprotein after activation of the nuclear receptor farnesoid X
receptor. Circ Res. 2013 Jun 7;112(12):1602-12. doi:
10.1161/CIRCRESAHA.112.300648. Epub 2013 Mar 21. PubMed PMID: 23519696; PubMed
Central PMCID: PMC3995747.
4: Bass JY, Caravella JA, Chen L, Creech KL, Deaton DN, Madauss KP, Marr HB,
McFadyen RB, Miller AB, Mills WY, Navas F 3rd, Parks DJ, Smalley TL Jr, Spearing
PK, Todd D, Williams SP, Wisely GB. Conformationally constrained farnesoid X
receptor (FXR) agonists: heteroaryl replacements of the naphthalene. Bioorg Med
Chem Lett. 2011 Feb 15;21(4):1206-13. doi: 10.1016/j.bmcl.2010.12.089. Epub 2010
Dec 23. PubMed PMID: 21256005.
